Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UKNHS system
Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UKNHS system
复制标题
DOI：
10.1007/s10198-006-0034-1
复制
发表时间：
2007-06-01
影响因子：
4.4
通讯作者：
Launois, R.
中科院分区：
文献类型：
--
作者：
Le Lay, K.;Myon, E.;Launois, R.
国家健康与临床卓越研究所推荐长春瑞滨(VNB)、紫杉醇、多西紫杉醇和吉西他滨治疗非小细胞肺癌。编制了一个经济模型，以确定这些药物的比较成本，包括从联合王国国家卫生系统的角度来看，VNB的新口服配方。临床疗效是根据已发表的试验确定的。药物获取、给药、毒性管理和患者运输成本的计算来自参考出版物。马尔科夫模型被用来估计52周内每个患者的成本。静脉注射VNB、吉西他滨、紫杉醇和多西紫杉醇的年随访成本分别为3,746英镑、5,332英镑、5,977英镑和6,766英镑，而口服VNB在第1天门诊给药，每21天在家自我给药，每名患者每年的成本为2,888英镑。口服VNB可进一步节省医院资源。
The National Institute for Health and Clinical Excellence recommends vinorelbine (VNB), paclitaxel, docetaxel, and gemcitabine in the treatment of non-small cell lung cancer. An economic model was prepared to determine the comparative cost of these agents, including the new oral formulation of VNB from a United Kingdom National Health System perspective. Clinical effectiveness was determined from published trials. Costs of drug acquisition, administration, toxicity management, and patient transportation costs were calculated from reference publications. A Markov model was used to estimate the cost per patient over 52 weeks. Intravenous VNB, gemcitabine, paclitaxel, and docetaxel incur annual follow-up costs of 3,746 pound, 5,332 pound, 5,977 pound, and 6,766 pound, respectively, while oral VNB with outpatient administration on d1, and self-administration at home on d8 every 21 days has a cost per patient per year of 2,888 pound. Oral VNB allows further hospital resources savings.